Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: C3 Glomerulopathy (C3G) Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 22, 2026, 12:54 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
5
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
C3G
Interventions
Placebo, iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Complement Mediated Diseases
Interventions
AMY-101
Drug
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced May 22, 2026, 12:54 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions
ADX-097
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced May 22, 2026, 12:54 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
C3 Glomerulopathy
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
C3 Glomerulopathy (C3G)
Interventions
Avacopan, Avacopan Matching Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Chicago, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced May 22, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 12:54 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Dense Deposit Disease
Interventions
TP10
Drug
Lead sponsor
University of Iowa
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced May 22, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced May 22, 2026, 12:54 AM EDT